[go: up one dir, main page]

CY1110590T1 - Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα - Google Patents

Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα

Info

Publication number
CY1110590T1
CY1110590T1 CY20101100065T CY101100065T CY1110590T1 CY 1110590 T1 CY1110590 T1 CY 1110590T1 CY 20101100065 T CY20101100065 T CY 20101100065T CY 101100065 T CY101100065 T CY 101100065T CY 1110590 T1 CY1110590 T1 CY 1110590T1
Authority
CY
Cyprus
Prior art keywords
selective
eukaryotic cells
recombination
dna sequencing
sequence
Prior art date
Application number
CY20101100065T
Other languages
English (en)
Inventor
Peter Dröge
Nicole Christ
Elke Lorbach
Original Assignee
Peter Dröge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Dröge filed Critical Peter Dröge
Publication of CY1110590T1 publication Critical patent/CY1110590T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μέθοδο για τον επιλεκτικό ως προς την αλληλουχία ανασυνδυασμό του DNA εντός ευκαρυωτικών κυττάρων, που περιλαμβάνει την εισαγωγή σε κύτταρο μίας πρώτης DNA-αλληλουχίας, την εισαγωγή σε κύτταρο μίας δεύτερης DNA-αλληλουχίας, και την εκτέλεση του επιλεκτικού ως προς την αλληλουχία ανασυνδυασμού μέσω επίδρασης ιντεγκράσης Int βακτηριοφάγου λ. Μία προτιμώμενη μορφή εφαρμογής αναφέρεται σε μέθοδο, που περαιτέρω περιλαμβάνει την εκτέλεση ενός δεύτερου επιλεκτικού ως προς την αλληλουχία ανασυνδυασμού του DNA μέσω επίδρασης της Int και του παράγοντα Xis. Η παρούσα εφεύρεση αναφέρεται περαιτέρω σε φορείς και στη χρήση αυτών ως φαρμακευτικά μέσα.
CY20101100065T 1999-08-30 2010-01-21 Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα CY1110590T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941186A DE19941186A1 (de) 1999-08-30 1999-08-30 Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
EP06008807A EP1681355B1 (de) 1999-08-30 2000-08-29 Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen

Publications (1)

Publication Number Publication Date
CY1110590T1 true CY1110590T1 (el) 2015-04-29

Family

ID=7920135

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101290T CY1105288T1 (el) 1999-08-30 2006-09-11 Αλληλουχιοειδικος dna ανασυνδυασμος εντος ευκαρυωτικων κυτταρων
CY20101100065T CY1110590T1 (el) 1999-08-30 2010-01-21 Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061101290T CY1105288T1 (el) 1999-08-30 2006-09-11 Αλληλουχιοειδικος dna ανασυνδυασμος εντος ευκαρυωτικων κυτταρων

Country Status (19)

Country Link
US (2) US20030027337A1 (el)
EP (2) EP1681355B1 (el)
JP (1) JP2003520028A (el)
KR (1) KR100490188B1 (el)
CN (1) CN1182247C (el)
AT (2) ATE446373T1 (el)
AU (1) AU776297B2 (el)
CA (1) CA2390526C (el)
CY (2) CY1105288T1 (el)
CZ (1) CZ302620B6 (el)
DE (3) DE19941186A1 (el)
DK (2) DK1214440T3 (el)
ES (2) ES2267567T3 (el)
HK (1) HK1047129B (el)
IL (2) IL148152A0 (el)
MX (1) MX244498B (el)
PT (2) PT1214440E (el)
SK (1) SK286034B6 (el)
WO (1) WO2001016345A2 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
IL135776A0 (en) * 1997-10-24 2001-05-20 Life Technologies Inc Recombinational cloning using nucleic acids having recombination sites
ATE443074T1 (de) 1999-03-02 2009-10-15 Life Technologies Corp Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
CA2392753A1 (en) 1999-12-10 2001-06-14 Invitrogen Corporation Use of multiple recombination sites with unique specificity in recombinational cloning
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030077804A1 (en) * 2001-04-19 2003-04-24 Invitrogen Corporation Compositions and methods for recombinational cloning of nucleic acid molecules
CA2448505A1 (en) * 2001-05-21 2002-11-28 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
EP1401849A4 (en) * 2001-05-30 2005-05-18 Chromos Molecular Systems Inc ARTIFICIAL PLANT CHROMOSOMES, THEIR USE AND METHOD FOR THE MANUFACTURE OF ARTIFICIAL PLANT CHROMOSOMES
IL157746A0 (en) * 2001-05-30 2004-03-28 Chromos Molecular Systems Inc Chromosome-based platforms
US20060130179A1 (en) 2002-03-29 2006-06-15 Suttie Janet L Lambda integrase mediated recombination in plants
WO2004009768A2 (en) * 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
US7491539B2 (en) 2002-12-05 2009-02-17 Boehringer Ingelheim Pharma Kg Sequence specific DNA recombination in eukaryotic cells
TW200502390A (en) 2002-11-28 2005-01-16 Peter Droege Sequence specific DNA recombination in eukaryotic cells
EP1644538A4 (en) * 2003-06-26 2006-11-08 Invitrogen Corp METHODS AND COMPOSITIONS FOR DETECTING PROMOTER ACTIVITY AND EXPRESSING FUSION PROTEINS
EP1687323A4 (en) 2003-08-08 2009-08-12 Life Technologies Corp METHODS AND COMPOSITIONS FOR DIRECT CLONING OF NUCLEIC ACID MOLECULES
JP2007512838A (ja) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション 組換え部位を含む核酸分子およびその使用方法
US7935862B2 (en) 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
KR101327245B1 (ko) 2006-06-03 2013-11-12 신젠타 파티서페이션즈 아게 옥수수 이벤트 ｍｉｒ162
KR101608225B1 (ko) * 2007-11-30 2016-04-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 신규한 재조합 서열
CN102604936B (zh) * 2011-01-21 2013-09-04 上海市儿童医院 羊基因组中被噬菌体*c31整合酶识别的dna及其应用
WO2013018096A1 (en) 2011-08-03 2013-02-07 Ramot At Tel-Aviv University Ltd. Use of integrase for targeted gene expression
CN102533741B (zh) * 2011-12-09 2014-09-24 深圳华大基因研究院 猪假attp位点及其用途
US11078493B2 (en) 2016-06-21 2021-08-03 Nanyang Technological University Site-specific DNA recombination
FI3638776T3 (fi) 2017-06-14 2025-12-09 Univ Dresden Tech Menetelmiä ja välineitä genomien geneettiseen muokkaamiseen hyödyntäen suunnittelu-DNA:ta rekombinoivia entsyymejä
US20250354175A1 (en) * 2022-06-07 2025-11-20 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Attp mv4-derived site-specific recombination and its use for integration of sequence of interest

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US7118911B1 (en) * 1990-03-05 2006-10-10 Genzyme Corporation DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5861273A (en) * 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
NZ500843A (en) * 1995-06-07 2002-03-28 Invitrogen Corp A method of DNA recombination which is selectable to select for cells containing a product and against cells only harbouring the insert donor
DE19530412A1 (de) * 1995-08-18 1997-02-20 Harald Von Prof Dr Melchner Selbst deletierende retrovirale Vektoren für die Gentherapie
FR2741892B1 (fr) * 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5928914A (en) * 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
CA2269661A1 (en) * 1996-12-18 1998-06-25 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
IL135776A0 (en) * 1997-10-24 2001-05-20 Life Technologies Inc Recombinational cloning using nucleic acids having recombination sites
US6632672B2 (en) * 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification

Also Published As

Publication number Publication date
PT1214440E (pt) 2006-11-30
CN1387576A (zh) 2002-12-25
CZ302620B6 (cs) 2011-08-03
CY1105288T1 (el) 2010-03-03
ES2267567T3 (es) 2007-03-16
EP1214440B1 (de) 2006-06-28
WO2001016345A2 (de) 2001-03-08
EP1214440A2 (de) 2002-06-19
IL148152A0 (en) 2002-09-12
ATE446373T1 (de) 2009-11-15
HK1047129A1 (en) 2003-02-07
KR100490188B1 (ko) 2005-05-17
DE50013093D1 (de) 2006-08-10
HK1047129B (zh) 2006-10-20
DE50015772D1 (de) 2009-12-03
DE19941186A1 (de) 2001-03-01
ES2334577T3 (es) 2010-03-12
SK286034B6 (sk) 2008-01-07
CN1182247C (zh) 2004-12-29
CZ2002756A3 (cs) 2002-06-12
EP1681355A1 (de) 2006-07-19
JP2003520028A (ja) 2003-07-02
CA2390526C (en) 2010-10-19
US20130133092A1 (en) 2013-05-23
IL148152A (en) 2007-10-31
MXPA02002036A (es) 2003-08-20
SK3042002A3 (en) 2002-07-02
WO2001016345A3 (de) 2001-12-06
KR20020057953A (ko) 2002-07-12
AU7642900A (en) 2001-03-26
CA2390526A1 (en) 2001-03-08
ATE331802T1 (de) 2006-07-15
PT1681355E (pt) 2010-01-27
US20030027337A1 (en) 2003-02-06
DK1214440T3 (da) 2006-10-30
AU776297B2 (en) 2004-09-02
MX244498B (es) 2007-03-28
EP1681355B1 (de) 2009-10-21
DK1681355T3 (da) 2009-12-14

Similar Documents

Publication Publication Date Title
CY1110590T1 (el) Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
CY1117729T1 (el) Μεθοδοι για την παρασκευη κυτταροτοξικων συζευγματων μεϋτανσινοειδων και παραγοντων δεσμευσης κυτταρου
ATE466932T1 (de) Vermehrung von viren in zellkultur
DK0762898T3 (da) Cyclodextrinsystem til levering af oligonukleotider til celler
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
CY1105286T1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
DE60037450D1 (de) Funf-helix protein
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
TR200100054T2 (tr) Paroksetin metansülfonat
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
BR9811094A (pt) Agente terapêutico para tumores linfáticos
TR200201071T2 (tr) Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi
NO963872L (no) Forgrenede polyoksyalkylen-makromolekyler, fremgangsmåte ved deres fremstilling og deres anvendelser
AR017368A1 (es) Un procedimiento para la insercion de adn foraneo en una celula hospedante, un vector recombinante utilizado en dicho procedimiento y el uso del mismo
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
CR7058A (es) Peptidos humanos sinteticos y composiciones farmaceuticas que los contienen para el tratamiento de lupus eritematoso sistemico
DE60007120D1 (de) Isophosphoramide-senfgasanalogen und deren verwendung
SE9803272D0 (sv) A drug for cell regeneration
DE60143668D1 (de) Peptidinhibitoren gegen den eintritt von hiv in zellen
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
TW200502390A (en) Sequence specific DNA recombination in eukaryotic cells
DE60313444D1 (de) Vegf-peptide und deren verwendung
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους